接受连续性静脉-静脉血液透析滤过(CVVHDF)治疗的患者中万古霉素群体药代动力学模型的探索
本研究为回顾性单中心三级ICU研究,纳入2015年1月至2016年7月同时接受万古霉素和CVVHDF的患者,采用一室模型进行群体药代动力学分析,共分析24例患者的106个给药间隔(155个浓度点)。基础模型可接受(Obs-Pred R²=0.78),未发现连续协变量能明确改善模型;纳入抗凝方式和升压药使用作为分类协变量后药代参数估计相似,使用局部枸橼酸抗凝或未用升压药时参数估计变异性有降低趋势。PTA模拟提示需2 g负荷剂量后750 mg每12小时维持(负荷后12小时开始),以达到早期目标谷浓度至少15 mg/L。
要点
- 对CVVHDF危重患者,PTA模拟提示2 g负荷剂量后750 mg每12小时维持(负荷后12小时开始)可达早期目标谷浓度至少15 mg/L。
- 共分析24例患者的106个给药间隔(155个浓度点),一室基础模型Obs-Pred R²=0.78。
- 未发现任何连续协变量能明确改善基础模型。
- 纳入抗凝方式和升压药使用作为分类协变量后药代参数估计相似,使用局部枸橼酸抗凝或未用升压药时参数估计变异性有降低趋势。
适用人群与场景
- 接受CVVHDF并同时使用万古霉素的危重患者,来自单中心三级ICU,纳入时间为2015年1月至2016年7月。
处置流程与药物剂量
- PTA模拟提示:2 g负荷剂量后,750 mg每12小时维持,于负荷后12小时开始给药,以达到早期目标谷浓度至少15 mg/L。
研究设计与关键结果
- 回顾性单中心三级ICU研究,共纳入24例患者、106个万古霉素给药间隔(155个浓度点)。
- 一室基础模型可接受,观测浓度与群体预测浓度(Obs-Pred)R²=0.78。
- 未发现任何连续协变量能明确改善基础模型。
- 纳入抗凝方式和升压药使用作为分类协变量后药代参数估计相似,使用局部枸橼酸抗凝或未用升压药时参数估计变异性有降低趋势。
- PTA模拟提示需2 g负荷剂量后750 mg每12小时维持(负荷后12小时开始),以达到早期目标谷浓度至少15 mg/L。
证据类型、等级与局限
- 证据类型:回顾性单中心群体药代动力学分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对CVVHDF危重患者,PTA模拟提示2 g负荷剂量后750 mg每12小时维持(负荷后12小时开始)可在治疗早期达到至少15 mg/L的目标谷浓度。
- 使用局部枸橼酸抗凝或未用升压药时药代参数估计变异性有降低趋势。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Therapeutic antibiotic dose monitoring can be particularly challenging in septic patients requiring renal replacement therapy. Our aim was to conduct an exploratory population pharmacokinetic (PK) analysis on PK of vancomycin following intermittent infusion in critically ill patients receiving continuous venovenous haemodiafiltration (CVVHDF); focussing on the influence of dialysis-related covariates.
METHODS: This was a retrospective single-centre tertiary level intensive care unit (ICU) study, which included patients treated concurrently with vancomycin and CVVHDF between January 2015 and July 2016. We extracted clinical, laboratory and dialysis data from the electronic healthcare record (EHR), using strict inclusion criteria. A population PK analysis was conducted with a one-compartment model using the PMetrics population PK modelling package. A base structural model was developed, with further analyses including clinical and dialysis-related data to improve model prediction through covariate inclusion. The final selected model simulated patient concentrations using probability of target attainment (PTA) plots to investigate the probability of different dosing regimens achieving target therapeutic concentrations.
RESULTS: A total of 106 vancomycin dosing intervals (155 levels) in 24 patients were examined. An acceptable 1-compartment base model was produced (Plots of observed vs. population predicted concentrations (Obs-Pred) R2 = 0.78). No continuous covariates explored resulted in a clear improvement over the base model. Inclusion of anticoagulation modality and vasopressor use as categorical covariates resulted in similar PK parameter estimates, with a trend towards lower parameter estimate variability when using regional citrate anti-coagulation or without vasopressor use. Simulations using PTA plots suggested that a 2 g loading dose followed by 750 mg 12 hourly as maintenance dose, commencing 12 h after loading, is required to achieve adequate early target trough concentrations of at least 15 mg/L.
CONCLUSIONS: PTA simulations suggest that acceptable trough vancomycin concentrations can be achieved early in treatment with a 2 g loading dose and maintenance dose of 750 mg 12 hourly for critically ill patients on CVVHDF.
参考来源
- Kirwan M, Munshi R, O'Keeffe H, et al. Exploring population pharmacokinetic models in patients treated with vancomycin during continuous venovenous haemodiafiltration (CVVHDF). Crit Care. 2021. PMID: 34930430. doi:10.1186/s13054-021-03863-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。